Citadel Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $352K | Buy |
13,000
+2,900
| +29% | +$97.5K | ﹤0.01% | 10116 |
|
|
2025
Q4 | $433K | Sell |
10,100
-11,300
| -53% | -$426K | ﹤0.01% | 9371 |
|
|
2025
Q3 | $606K | Buy |
+21,400
| New | +$640K | ﹤0.01% | 8655 |
|
|
2025
Q2 | – | Sell |
-8,800
| Closed | -$158K | – | 14669 |
|
|
2025
Q1 | $158K | Buy |
8,800
+6,800
| +340% | +$138K | ﹤0.01% | 10788 |
|
|
2024
Q4 | $33.6K | Sell |
2,000
-4,320
| -68% | -$82.9K | ﹤0.01% | 12765 |
|
|
2024
Q3 | $102K | Buy |
6,320
+3,130
| +98% | +$36.8K | ﹤0.01% | 11082 |
|
|
2024
Q2 | $26.2K | Buy |
3,190
+2,850
| +838% | +$29.8K | ﹤0.01% | 12400 |
|
|
2024
Q1 | $5.03K | Sell |
340
-100
| -23% | -$1.35K | ﹤0.01% | 13773 |
|
|
2023
Q4 | $6.38K | Sell |
440
-420
| -49% | -$4.29K | ﹤0.01% | 13354 |
|
|
2023
Q3 | $9.29K | Buy |
860
+110
| +15% | +$1.32K | ﹤0.01% | 13136 |
|
|
2023
Q2 | $9.68K | Sell |
750
-250
| -25% | -$3.38K | ﹤0.01% | 13247 |
|
|
2023
Q1 | $13.2K | Sell |
1,000
-120
| -11% | -$1.91K | ﹤0.01% | 13371 |
|
|
2022
Q4 | $16.8K | Buy |
1,120
+60
| +6% | +$550 | ﹤0.01% | 13271 |
|
|
2022
Q3 | $13K | Sell |
1,060
-770
| -42% | -$10.4K | ﹤0.01% | 12208 |
|
|
2022
Q2 | $21K | Buy |
1,830
+800
| +78% | +$16.1K | ﹤0.01% | 12387 |
|
|
2022
Q1 | $31K | Sell |
1,030
-2,160
| -68% | -$58.5K | ﹤0.01% | 13088 |
|
|
2021
Q4 | $85K | Sell |
3,190
-1,240
| -28% | -$37.4K | ﹤0.01% | 12879 |
|
|
2021
Q3 | $161K | Sell |
4,430
-1,380
| -24% | -$54.3K | ﹤0.01% | 12278 |
|
|
2021
Q2 | $252K | Sell |
5,810
-790
| -12% | -$29.8K | ﹤0.01% | 11679 |
|
|
2021
Q1 | $226K | Sell |
6,600
-3,850
| -37% | -$152K | ﹤0.01% | 11467 |
|
|
2020
Q4 | $366K | Buy |
10,450
+6,470
| +163% | +$187K | ﹤0.01% | 8725 |
|
|
2020
Q3 | $96K | Buy |
3,980
+2,680
| +206% | +$65.8K | ﹤0.01% | 9292 |
|
|
2020
Q2 | $24K | Buy |
+1,300
| New | +$23.4K | ﹤0.01% | 9512 |
|
|
2019
Q3 | – | Sell |
-8,260
| Closed | -$216K | – | 9669 |
|
|
2019
Q2 | $216K | Buy |
8,260
+6,390
| +342% | +$144K | ﹤0.01% | 8084 |
|
|
2019
Q1 | $48K | Sell |
1,870
-2,960
| -61% | -$67.7K | ﹤0.01% | 8835 |
|
|
2018
Q4 | $111K | Sell |
4,830
-2,190
| -31% | -$61.8K | ﹤0.01% | 8207 |
|
|
2018
Q3 | $225K | Buy |
7,020
+3,350
| +91% | +$101K | ﹤0.01% | 8030 |
|
|
2018
Q2 | $104K | Sell |
3,670
-1,200
| -25% | -$42.7K | ﹤0.01% | 8221 |
|
|
2018
Q1 | $172K | Buy |
4,870
+2,910
| +148% | +$116K | ﹤0.01% | 7453 |
|
|
2017
Q4 | $76K | Buy |
1,960
+750
| +62% | +$28.5K | ﹤0.01% | 7513 |
|
|
2017
Q3 | $31K | Sell |
1,210
-1,090
| -47% | -$26.5K | ﹤0.01% | 7282 |
|
|
2017
Q2 | $63K | Buy |
+2,300
| New | +$63K | ﹤0.01% | 7043 |
|
|
2017
Q1 | – | Sell |
-1,320
| Closed | -$31K | – | 7936 |
|
|
2016
Q4 | $31K | Sell |
1,320
-2,790
| -68% | -$79.9K | ﹤0.01% | 6983 |
|
|
2016
Q3 | $151K | Buy |
4,110
+3,030
| +281% | +$86.9K | ﹤0.01% | 6463 |
|
|
2016
Q2 | $24K | Buy |
+1,080
| New | +$26.9K | ﹤0.01% | 6561 |
|
|
2016
Q1 | – | Sell |
-1,060
| Closed | -$32K | – | 7770 |
|
|
2015
Q4 | $32K | Buy |
1,060
+200
| +23% | +$6.06K | ﹤0.01% | 7627 |
|
|
2015
Q3 | $21K | Sell |
860
-1,240
| -59% | -$37K | ﹤0.01% | 8126 |
|
|
2015
Q2 | $67K | Buy |
2,100
+1,850
| +740% | +$70.7K | ﹤0.01% | 7446 |
|
|
2015
Q1 | $9K | Buy |
+250
| New | +$6.86K | ﹤0.01% | 8222 |
|
|
2014
Q3 | – | Sell |
-40
| Closed | -$1K | – | 8354 |
|
|
2014
Q2 | $1K | Sell |
40
-200
| -83% | -$6.8K | ﹤0.01% | 7886 |
|
|
2014
Q1 | $9K | Sell |
240
-80
| -25% | -$2.85K | ﹤0.01% | 7544 |
|
|
2013
Q4 | $9K | Sell |
320
-1,710
| -84% | -$50.2K | ﹤0.01% | 6733 |
|
|
2013
Q3 | $73K | Buy |
2,030
+1,120
| +123% | +$40.9K | ﹤0.01% | 5565 |
|
|
2013
Q2 | $30K | Buy |
+910
| New | +$41.2K | ﹤0.01% | 5903 |
|
Other funds holding RIGL
AC
VCM
Citadel Advisors's RIGL Position: Q1 2026 in Review
Citadel Advisors reduced its Rigel Pharmaceuticals (RIGL) stake by 29% in Q1 2026, selling an estimated $1.82M and leaving 131,199 shares worth $3.55M. The position accounts for ﹤0.01% of the portfolio, ranked #4935.
Citadel Advisors first reported a position in RIGL in Q2 2013 and has held it in 48 quarters since. The position peaked at $22.2M in Q4 2020. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.
- Citadel Advisors held 131,199 shares of Rigel Pharmaceuticals worth $3.55M as of Q1 2026.
- Citadel Advisors sold 54,220 Rigel Pharmaceuticals shares in Q1 2026, an estimated $1.82M.
- Rigel Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4935 holding.
- Citadel Advisors first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
- Citadel Advisors's Rigel Pharmaceuticals position peaked at $22.2M in Q4 2020.
- 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.